Zhicheng TAVR Robot

Inclusion Criteria: * Age ≥65 years old, gender is not limited; * Patients assessed by a cardiac multidisciplinary team (MDT) expert panel as having severe aortic stenosis and suitable for transcatheter aortic valve replacement; \*Severe aortic stenosis was defined as echocardiographically demonstrated transaortic valve flow velocity ≥4.0 m/s, or transaortic valve pressure differential ≥40 mmHg (1 mmHg=0.133 kPa), or aortic orifice area \<1.0 cm2, or effective aortic orifice area index \<0.6 cm2/m2; for low-pressure-differential-low-flow rate by dopa-phenobutylamine loading test, Doppler ultrasound evaluation or other imaging means of assessment for those judged to have severe aortic stenosis. * Have a core laboratory assessment that the patient is anatomically suitable for transcatheter aortic valve replacement; * Patients who understand the purpose of the trial, voluntarily participate in the trial, sign an informed consent form, and are willing to cooperate in the follow-up. Exclusion Criteria: * Patients whose access or aortic root anatomical pattern is unsuitable for TAVR treatment; * Poor peripheral arterial conditions that preclude transfemoral TAVR; * Aortic annulus horizontal pinch angle ≥65° as measured by preoperative MDCT; * Patients at high risk of coronary obstruction requiring intraoperative coronary protection measures; * Patients requiring intraoperative delivery with a grapple assist system; * Previous implantation of a prosthetic aortic valve (bioprosthetic or mechanical); * Active stage of infective endocarditis or other active infection; * Combined mitral, tricuspid or severe macrovascular lesions requiring surgical or interventional intervention; * Echocardiography suggestive of left ventricular thrombus, intracardiac mass or redundant organisms; * Diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, infiltrative cardiomyopathy (e.g. amyloidosis, haemochromatosis, nodular disease, etc.), constrictive pericarditis; * Severe obstruction of the left ventricular outflow tract without corrective measures; * Severe pulmonary hypertension (pulmonary artery systolic pressure \>70 mmHg measured by ultrasound); * Severe right heart dysfunction as suggested by a combined clinical and ultrasound assessment; * Severe left heart systolic insufficiency (left ventricular ejection fraction \<30%); * Cardiogenic shock or haemodynamic instability requiring ventricular assist device therapy within 30 days prior to enrolment; * End-stage heart failure (ACC/AHA Stage D), or post cardiac transplantation, or awaiting cardiac transplantation; * Acute myocardial infarction within 30 days prior to enrolment; * Has had a stroke within 3 months prior to enrolment; * Stenosis of the common or internal carotid artery or vertebral artery (\>70% stenosis) requiring treatment as recommended by the relevant disciplinary consultation; * Severe cardiac and aortic disease requiring concomitant treatment, including ascending aortic aneurysm (maximum diameter ≥ 50 mm); * Severe renal insufficiency (estimated glomerular filtration rate \<30mL/min/1.73m2); * Active peptic ulcer or history of upper gastrointestinal bleeding within 3 months prior to enrolment; * Severe coagulopathy; Patients with known intolerance to anticoagulant, antiplatelet drugs or anaesthetic drugs; Patients who have participated in other drug or medical device clinical trials prior to enrolment that have not met the primary endpoint; Patients who, in the opinion of the investigator, are not suitable for participation in this clinical trial